United States - English - NLM (National Library of Medicine)

elevated dermatology and skin - titanium dioxide 7.2%, zinc oxide 4.0%. - sunscreen helps prevent sunburn.

United States - English - NLM (National Library of Medicine)

elevated dermatology and skin - titanium dioxide 7.75%, zinc oxide 10.0%. - sunscreen helps prevent sunburn.

United States - English - NLM (National Library of Medicine)

elevated mountain distilling company - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Australia - English - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 43168 - non-constrained polyethylene acetabular liner - vivacit-e hxpe elevated rim liners are manufactured from vitamin e (?-tocopherol) blended, hxpe. each liner is identified with 2 letter code corresponding to the mating acetabular shell. liners are secured to the respective shell by engaging a protruding pe rim with an integrated locking groove in the shell. features 15? elevated rim. approximately 120? of the liner face is elevated to provide additional femoral head coverage, resulting in slight rom decrease. for cemented and uncemented use. the vivacit-e vitamin e highly xlpe elevated rim liners are a component of the continuum?, trilogy? it, and allofit? it alloclassic?, and is indicated for primary or revision surgery in skeletally mature individuals for rehabilitating hips damaged as a result of noninflammatory degenerative joint disease (nidjd) or its composite diagnoses of osteoarthritis, avascular necrosis, protrusio acetabuli, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.

Australia - English - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 43168 - non-constrained polyethylene acetabular liner - the longevity? it elevated liner is a component of the continuum?, trilogy? it, allofit? it acetabular systems. available in 15? elevated rim configuration. approximately 120? of the liner face is elevated in order to provide additional femoral head coverage in one hemisphere. manufactured from longevity?, a highly crosslinked ultra-high molecular weight polyethylene (hxpe). intended for uncemented use. the longevity? it elevated rim liner is indicated for primary or revision surgery in skeletally mature individuals for rehabilitating hips damaged as a result of noninflammatory degenerative joint disease (nidjd) or its composite diagnoses of osteoarthritis, avascular necrosis, protrusio acetabuli, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant

Australia - English - Department of Health (Therapeutic Goods Administration)

zimmer biomet pty ltd - 43168 - non-constrained polyethylene acetabular liner - the ultra-high molecular-weight polyethylene (uhmwpe) liner, is offered in a variety of inner diameters. the elevated liners provide optimal femoral head coverage. the liner is locked into the shell component once the metal shell has been secured in the acetabulum. a tivanium alloy locking ring, provided preassembled to the shell, secures the liner to the shell longevity cross-linked polyethylene liners are part of the trilogy acetabular system that is indicated for either cemented or uncemented use in skeletally mature individuals undergoing primary or revision surgery for rehabilitating hips damaged as a result of non-inflammatory degenerative joint disease (nidjd) or its composite diagnoses of osteoarthritis, avascular necrosis, protrusio acetabuli, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.

Israel - English - Ministry of Health

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

European Union - English - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressants - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids).ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 45mg/vial - ustekinumab 45mg/vial

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson pte. ltd. - ustekinumab - injection, solution - 90mg/vial - ustekinumab 90mg/vial